{"id":"W2551867019","doi":"10.1111/apt.13838","title":"Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy","year":2016,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"UCB Pharma; Relypsa; Takeda Oncology; Genentech; Norgine; Tillotts Pharma; Astellas Pharma; Celltrion; Eisai; Ironwood Pharmaceuticals, Incorporated; Therakos; AbbVie; Novo Nordisk; Teva Pharmaceutical Industries; Gilead Sciences; Procter and Gamble; Celgene; Pfizer; Biogen; GlaxoSmithKline; Shire; Orexigen Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Atlantic Healthcare; Amgen; ActoGeniX; Sanofi; Zalicus; Abbott Laboratories","keywords":"Adalimumab; Medicine; Ulcerative colitis; Combination therapy; Internal medicine; Adverse effect; Maintenance therapy; Crohn's disease; Placebo; Concomitant; Gastroenterology; Disease; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008730214,0.0004303406,0.001849335,0.0005416093,0.000274657,0.0009898253,0.0003350708,0.0007375839,0.001499785],"category_scores_gemma":[0.01259475,0.00036717,0.002593864,0.0006523886,0.0005387777,0.0007609407,0.0003702582,0.0008479183,0.00014741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005253612,"about_ca_system_score_gemma":0.0003528876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001659753,"about_ca_topic_score_gemma":0.0004236288,"domain_scores_codex":[0.9952582,0.002886474,0.0007904247,0.0003723126,0.0005263622,0.0001663039],"domain_scores_gemma":[0.9797745,0.01404258,0.004463433,0.0005312925,0.0005687408,0.0006194632],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5787078,0.002215496,0.2788344,0.00564398,0.0177652,0.000588418,0.0005338303,0.001017657,0.006806466,0.0001306787,0.0003453322,0.1074107],"study_design_scores_gemma":[0.06812409,0.322729,0.5722297,0.001140266,0.02351312,0.002167154,0.0003264366,0.001237902,0.004438526,0.0002373819,0.003749044,0.0001073393],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9494739,0.04937574,0.0001486873,0.0001074324,0.00003590225,0.0001175676,0.0001358446,0.000005286146,0.0005995281],"genre_scores_gemma":[0.9970169,0.002459845,0.0002052474,0.00006712934,0.00005833082,0.00005102938,0.00008722347,0.000001794414,0.00005241198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008730214,"threshold_uncertainty_score":0.04617035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007973978760768238,"score_gpt":0.25191173948789,"score_spread":0.2439377607271218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}